Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area

Mar 5, 2024 8:30 AM ET

Campaign: Corporate Social Responsibility

" " — Daniel O’Day and a group of Gilead employees visited with San Francisco Community Health Center staff last fall. Image courtesy of San Francisco Business Times.

" " — Gilead employees at a volunteer event for the San Mateo-based Samaritan House. Image courtesy of San Francisco Business Times.

Originally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com

Much has changed since Daniel O’Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standing leadership in antiviral therapies to include a focus on cancer medicines. Today the Foster City-based company is the second-largest biotech employer in the Bay Area, and according to a Bay Area Council report, it created an estimated economic impact of $22.1 billion in 2020 alone. It has more than 25 marketed therapies for HIV, cancer, hepatitis, COVID-19 and other diseases, and one of the strongest and most diverse pipelines of new medicines in its history.

Continue reading here

Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area

More from Gilead Sciences

Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic

Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer

Gilead Foundation’s Healthcare Education, Access and Leadership (HEAL) Initiative Is Dedicating $5 Million to Help Build a More Diverse Bay Area Healthcare Workforce

Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer

Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic

Championing HIV Services for LGBTQ+ Youth

Working to Build Next-Generation Cancer Therapies

Helping End HIV - Gilead Sciences